|
Fernandez O, Montalban X, Aguera E, Aladro Y, Alonso A, Arroyo R, Brieva L, Calles C, Costa-Frossard L, Eichau S, Garcia-Dominguez JM, Hernandez MA, Landete L, Llaneza M, Llufriu S, Meca-Lallana JE, Meca-Lallana V, Mongay-Ochoa N, Moral E, Oreja-Guevara C, Ramio-Torrenta L, Tellez N, Romero-Pinel L, Rodriguez-Antiguedad A. [15th Post-ECTRIMS Meeting: a review of the latest developments presented at the 2022 ECTRIMS Congress (Part I)]. Rev Neurol. 2023 Jul 1;77(1):19-30. doi: 10.33588/rn.7701.2023167. Spanish. PubMed PMID: 37365721; PubMed Central PMCID: PMC10663806.
AÑO: 2023; IF: 0.8
|
37365721
|
Brieva L, Estruch BC, Merino JAG, Meca-Lallana V, Rio J, Rodriguez-Antiguedad A, Aguera E, Ara JR, Luque AA, Garcia CA, Blanco Y, Castillo-Trivino T, Costa-Frossard L, Gonzalez Platas M, Pascual LL, Llaneza-Gonzalez M, Gines MLM, Matias-Guiu J, Meca-Lallana JE, Bilbao MM, Sempere AP, Romero-Pinel L, Saiz A, Moral E. Disease modifying therapy switching in relapsing multiple sclerosis: A Delphi consensus of the demyelinating expert group of the Spanish society of neurology. Mult Scler Relat Disord. 2022 Jul;63:103805. doi: 10.1016/j.msard.2022.103805. Epub 2022 Apr 12. PubMed PMID: 35512501.
AÑO: 2022; IF: 4.0
|
|
Bar-Or A, Wiendl H, Montalban X, Alvarez E, Davydovskaya M, Delgado SR, Evdoshenko EP, Giedraitiene N, Gross-Paju K, Haldre S, Herrman CE, Izquierdo G, Karelis G, Leutmezer F, Mares M, Meca-Lallana JE, Mickeviciene D, Nicholas J, Robertson DS, Sazonov DV, Sharlin K, Sundaram B, Totolyan N, Vachova M, Valis M, Bagger M, Haring DA, Ludwig I, Willi R, Zalesak M, Su W, Merschhemke M, Fox EJ. Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study. Mult Scler. 2022 May;28(6):910-924. doi: 10.1177/13524585211044479. Epub 2021 Oct 4. PubMed PMID: 34605319; PubMed Central PMCID: PMC9024029.
AÑO: 2022; IF: 5.8
|
|
Carreon Guarnizo E, Hernandez Clares R, Castillo Trivino T, Meca Lallana V, Arocas Casan V, Iniesta Martinez F, Olascoaga Urtaza J, Meca Lallana JE. Experience with tocilizumab in patients with neuromyelitis optica spectrum disorders. Neurologia (Engl Ed). 2022 Apr;37(3):178-183. doi: 10.1016/j.nrleng.2018.12.021. Epub 2021 Feb 26. PubMed PMID: 35465911.
AÑO: 2022
|
|
Meca-Lallana JE, Gomez-Ballesteros R, Perez-Miralles F, Forero L, Sepulveda M, Calles C, Martinez-Gines ML, Gonzalez-Suarez I, Boyero S, Romero-Pinel L, Sempere AP, Meca-Lallana V, Querol L, Costa-Frossard L, Prefasi D, Maurino J. Impact of Neuromyelitis Optica Spectrum Disorder on Quality of Life from the Patients' Perspective: An Observational Cross-Sectional Study. Neurol Ther. 2022 Sep;11(3):1101-1116. doi: 10.1007/s40120-022-00356-6. Epub 2022 May 6. PubMed PMID: 35524037; PubMed Central PMCID: PMC9075919.
AÑO: 2022; IF: 3.7
|